Related Experiment Video
Updated: Jun 6, 2026

Implementing Patch Clamp and Live Fluorescence Microscopy to Monitor Functional Properties of Freshly Isolated PKD Epithelium
Published on: September 1, 2015
Clinical aspects of autosomal recessive polycystic kidney disease
Natasha Favoretto Dias1, Vivian Lanzarini, Luiz Fernando Onuchic
1Universidade de São Paulo, Brazil.
Insights
Autosomal Recessive Polycystic Kidney Disease (ARPKD) is a serious pediatric condition. Early diagnosis and intervention are crucial due to high rates of hypertension, kidney disease, and portal hypertension in patients.
Area of Science:
- Pediatric Nephrology
- Genetics
- Medical Research
Background:
- Autosomal Recessive Polycystic Kidney Disease (ARPKD) is a significant pediatric cause of illness and death.
- The disease presents with a wide range of clinical manifestations.
Purpose of the Study:
- To analyze the clinical presentation and progression of ARPKD in pediatric patients.
- To evaluate the frequency and age of onset of morbidities associated with ARPKD.
Main Methods:
- Retrospective review of clinical records for 25 pediatric patients diagnosed with ARPKD.
- Assessment of clinical presentation, comorbidities, and treatment using standardized forms.
- Evaluation of morbidity frequencies and age of onset.
Main Results:
- Median age at diagnosis was 61.45 months; 52% of patients were female.
- High initial prevalence of arterial hypertension (56%), urinary tract infections (40%), and portal hypertension (32%).
- Over a median follow-up of 152.2 months, prevalence increased for arterial hypertension (76%), CKD stage ≥ 2 (44%), UTIs (52%), and portal hypertension (68%).
Conclusions:
- ARPKD is associated with substantial and progressive morbidity, including hypertension, kidney disease, and liver complications.
- The high burden of disease underscores the need for an international database to facilitate early therapeutic support.
Introduction:
Autosomal Recessive Polycystic Kidney Disease (ARPKD) is an important pediatric cause of morbidity and mortality, with a variable clinical spectrum.
Methods:
The clinical presentation and evolution of 25 patients (Pts) were analyzed by clinical record review, according to the forms proposed by Guay-Woodford et al. Morbidities associated with the disease were evaluated with respect to their frequencies and age of onset.
Results:
The median age at the diagnosis was 61.45 months (0 to 336.5 months), with similar gender distribution (52% of the patients were female). A family ARPKD history was found in 20% of the cases (5/25), two of them associated with consanguinity. On arrival, arterial hypertension (SAH) was diagnosed in 56% of the Pts (14/25); chronic kidney disease stage ≥ 2 (CKD ≥ 2) in 24% (6/25); urinary tract infection (UTI) in 40% (10/25); and portal hypertension (PH) in 32% of the cases (8/25). Eighty percent of the initial abdominal ultrasonograms detected echogenic kidneys with gross cysts and 64% demonstrated normal liver and biliary ducts. ACE inhibitors were used in 36% of the analyzed patients, beta-blockers in 20%, calcium channel blockers in 28%, and diuretics in 36% of them. In the final evaluation, after an average follow-up time of 152.2 months (29.8 to 274.9 months), SAH was detected in 76% of the cases, CKD ≥ 2 in 44%, UTI in 52% and PH in 68%.
Conclusion:
The high morbidity and mortality associated with ARPKD justify the assembly of an international database, with the aim of establishing an early therapeutic support.
Related Concept Videos
Chronic Kidney Disease I: Introduction
Chronic Kidney Disease II: Clinical Manifestations
Nephrons
Chronic Kidney Disease III: Interprofessional Care
Diabetic Nephropathy
Nephrotic Syndrome I : Introduction

